MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: MiR-221 and miR-222 (miR-221/222) are frequently up-regulated in various types of human malignancy including glioblastoma. Recent studies have reported that miR-221/222 regulate cell growth and cell cycle progression by targeting p27 and p57. However the underlying mechanism involved in cell survival modulation of miR-221/222 remains elusive. Results: Here we showed that miR-221/222 inhibited cell apoptosis by targeting pro-apoptotic gene PUMA in human glioma cells. Enforced expression of miR-22/222 induced cell survival whereas knockdown of miR-221/222 rendered cells to apoptosis. Further, miR-221/222 reduced PUMA protein levels by targeting PUMA-3'UTR. Introducing PUMA cDNA without 3'UTR abrogated miR-221/222-induced cell survival. Notably, knockdown of miR-221/222 induces PUMA expression and cell apoptosis and considerably decreases tumor growth in xenograft model. Finally, there was an inverse relationship between PUMA and miR-221/222 expression in glioma tissues. Conclusion: To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhao, J.-J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., Coppola, D., & Cheng, J. Q. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806041200 · Cited by 509
Self-citationRetractedMicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053 · cited 1×
“Deregulation of miRNAs has been observed in various types of human malignancy, including lymphoma, colorectal cancer, lung cancer, breast cancer, papillary thyroid carcinoma, hepatocellular carcinoma and glioblastoma [1-7].”
BackgroundmicroRNAs as oncogenes and tumor suppressors
Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.028 · Cited by 2,749
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0637 · Cited by 2,354
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
Reduced accumulation of specific microRNAs in colorectal neoplasia.
Michael, M., Connor, S. M. O., Pellekaan, N. V. H., Young, G. P., & James, R. J. (2003) · PubMed · Cited by 1,775
PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280
The role of microRNA genes in papillary thyroid carcinoma
He, H., Jazdzewski, K., Li, W., Liyanarachchi, S., Nagy, R., Volinia, S., Calin, G. A., Liu, C.-G., Franssila, K., Suster, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509603102 · Cited by 1,215
Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T., & Shimotohno, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209283 · Cited by 1,147
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., et al. (2007) · Science · doi:10.1126/science.1133289 · Cited by 1,125
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096 · cited 2×
“Deregulation of miRNAs has been observed in various types of human malignancy, including lymphoma, colorectal cancer, lung cancer, breast cancer, papillary thyroid carcinoma, hepatocellular carcinoma and glioblastoma [1-7].”
BackgroundRegulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation
le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., Anile, C., Maira, G., Mercatelli, N., Ciafrè, S. A., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601790 · Cited by 815
MicroRNAs as Oncogenes and Tumor Suppressors
Chen, C.-Z. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058190 · Cited by 758
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Giovannini, C., Croce, C. M., Bolondi, L., et al. (2008) · Oncogene · doi:10.1038/onc.2008.178 · Cited by 639
High expression of precursor microRNA‐155/BIC RNA in children with Burkitt lymphoma
Metzler, M., Wilda, M., Busch, K., Viehmann, S., & Borkhardt, A. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10316 · Cited by 543
hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells
Shi, L., Cheng, Z., Zhang, J., Li, R., Zhao, P., Fu, Z., & You, Y. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.085 · Cited by 430
Self-citationZhou, X., Ren, Y., Moore, L., Mei, M., You, Y., Xu, P., Wang, B., Wang, G., Jia, Z., Pu, P., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.126 · Cited by 358
Self-citationMicroRNAs 221 and 222 Bypass Quiescence and Compromise Cell Survival
Medina, R., Zaidi, S. K., Liu, C.-G., Stein, J. L., vanWijnen, A. J., Croce, C. M., & Stein, G. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6754 · Cited by 308
Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition
Eyler, C. E., Foo, W.-C., LaFiura, K. M., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1073 · Cited by 242
PUMA- and Bax-induced autophagy contributes to apoptosis
Yee, K. S., Wilkinson, S., James, J., Ryan, K. M., & Vousden, K. H. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.28 · Cited by 236
Yamamichi, N., Shimomura, R., Inada, K.-I., Sakurai, K., Haraguchi, T., Ozaki, Y., Fujita, S., Mizutani, T., Furukawa, C., Fujishiro, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3257 · Cited by 173
miR-221/222 promote malignant progression of glioma through activation of the Akt pathway
Kang (2010) · International Journal of Oncology · doi:10.3892/ijo_00000570 · Cited by 130
Kang (2009) · International Journal of Oncology · doi:10.3892/ijo_00000296 · Cited by 125
Temozolomide-Mediated Radiosensitization of Human Glioma Cells in a Zebrafish Embryonic System
Geiger, G. A., Fu, W., & Kao, G. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6396 · Cited by 89
Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim
Jabbour, A. M., Heraud-Farlow, J. E., Daunt, C. P., Kaufmann, T., Sandow, J., O’Reilly, L. A., Callus, B. A., Lopez, A. F., Strasser, A., Vaux, D. L., et al. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.179 · Cited by 86
A natural antisense transcript, BOKAS, regulates the pro-apoptotic activity of human Bok
Zhang (2009) · International Journal of Oncology · doi:10.3892/ijo_00000241 · Cited by 60
Apoptosis-associated mitochondrial outer membrane permeabilization assays
Arnoult, D. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.003 · Cited by 46
Cited by
The role of MicroRNAs in human cancer
Peng, Y., & Croce, C. M. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.4 · Cited by 2,483
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S. M., & Voinea, S. C. (2020) · Cells · doi:10.3390/cells9020276 · Cited by 1,344
The BCL-2 protein family, BH3-mimetics and cancer therapy
Delbridge, A. R. D., & Strasser, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.50 · Cited by 531
Yu, B., Kim, H. W., Gong, M., Wang, J., Millard, R. W., Wang, Y., Ashraf, M., & Xu, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.043 · Cited by 473
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Metadata
- Authors
- Zhang, C.-Z., Zhang, J.-X., Zhang, A.-L., Shi, Z.-D., Han, L., Jia, Z.-F., Yang, W.-D., Wang, G.-X., Jiang, T., You, Y.-P., Pu, P.-Y., Cheng, J.-Q., & Kang, C.-S.
- Venue
- Molecular Cancer
- Published
- 2010-09-02
- Volume
- 9
- Issue
- 1
- Pages
- 229-229
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2162128852
- Cited by
- 314
- References
- 28
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.